Concomitant therapy in people with epilepsy: Potential drug-drug interactions and patient awareness

Epilepsy and Behavior

Volumn 31, Issue , 2014, Pages 369-376

  Eyal, Sara ^a   Rasaby, Sivan ^a,b,c   Ekstein, Dana ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Clalit Health Services   (Israel)

Author keywords

Antiepileptic drugs; Dietary supplements; Interactions; Patient awareness

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; PRESCRIPTION DRUG; SEROTONIN UPTAKE INHIBITOR;

ADJUVANT THERAPY; ADULT; ARTICLE; AWARENESS; CHEMICAL INTERACTION; DIET SUPPLEMENTATION; DRUG DRUG INTERACTION; EPILEPSY; FEMALE; FOOD COMPOSITION; HERB; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT; PEOPLE WITH EPILEPSY; PHARMACEUTICAL CARE; PROSPECTIVE STUDY;

ANTIEPILEPTIC DRUGS; DIETARY SUPPLEMENTS; INTERACTIONS; PATIENT AWARENESS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; AWARENESS; DATABASES, FACTUAL; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; PHYTOTHERAPY; PRESCRIPTION DRUGS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEX FACTORS; YOUNG ADULT;

EID: 84893010234     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2013.09.041     Document Type: Article

References (48)

1. Johannessen-Landmark C.J., Fossmark H., Larsson P.G., Rytter E., Johannessen S.I. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 2011, 95:51-59.
2. Johannessen-Landmark C.J., Rytter E., Johannessen S.I. Clinical use of antiepileptic drugs at a referral centre for epilepsy. Seizure 2007, 16:356-364.
3. Nicholas J.M., Ridsdale L., Richardson M.P., Ashworth M., Gulliford M.C. Trends in antiepileptic drug utilisation in UK primary care 1993-2008: cohort study using the General Practice Research Database. Seizure 2012, 21:466-470.
4. Tsiropoulos I., Gichangi A., Andersen M., Bjerrum L., Gaist D., Hallas J. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand 2006, 113:405-411.
5. Alexandre V., Capovilla G., Fattore C., Franco V., Gambardella A., Guerrini R., et al. Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. Epilepsia 2010, 51:921-925.
6. Gidal B.E., French J.A., Grossman P., Le Teuff G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 2009, 72:419-425.
7. Lackner T.E., Cloyd J.C., Thomas L.W., Leppik I.E. Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia 1998, 39:1083-1087.
8. Malerba A., Ciampa C., De Fazio S., Fattore C., Frassine B., La Neve A., et al. Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. Epilepsy Res 2010, 91:273-282.
9. Kaiboriboon K., Guevara M., Alldredge B.K. Understanding herb and dietary supplement use in patients with epilepsy. Epilepsia 2009, 50:1927-1932.
10. Easterford K., Clough P., Comish S., Lawton L., Duncan S. The use of complementary medicines and alternative practitioners in a cohort of patients with epilepsy. Epilepsy Behav 2005, 6:59-62.
11. Peebles C.T., McAuley J.W., Roach J., Moore J.L., Reeves A.L. Alternative medicine use by patients with epilepsy. Epilepsy Behav 2000, 1:74-77.
12. Sirven J.I., Drazkowski J.F., Zimmerman R.S., Bortz J.J., Shulman D.L., Macleish M. Complementary/alternative medicine for epilepsy in Arizona. Neurology 2003, 61:576-577.
13. Brodie M.J., Mintzer S., Pack A.M., Gidal B.E., Vecht C.J., Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern?. Epilepsia 2012, 54:11-27.
14. Hansten P.D., Horn J.R. Drug interactions analysis and management 2012, Wolters Kluwer Health.
15. Micromedex® DRUG-REAX system 2012-2013, Truven Health Analytics Inc.
16. Ekstein D., Schachter S.C. Natural products in epilepsy-the present situation and perspectives for the future. Pharmaceuticals 2010, 3:1426-1445.
17. Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003, 2:347-356.
18. Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003, 2:473-481.
19. Malone D.C., Abarca J., Hansten P.D., Grizzle A.J., Armstrong E.P., Van Bergen R.C., et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc 2004, 44:142-151.
20. Pack A.M. Antiepileptic drugs: are women aware of interactions with oral contraceptives and potential teratogenicity?. Epilepsy Behav 2009, 14:640-644.
21. Berg A.T., Berkovic S.F., Brodie M.J., Buchhalter J., Cross J.H., van Emde Boas W., et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010, 51:676-685.
22. Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Allen Hauser W., Mathern G., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
23. Leape L.L., Bates D.W., Cullen D.J., Cooper J., Demonaco H.J., Gallivan T., et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 1995, 274:35-43.
24. Bates D.W., Spell N., Cullen D.J., Burdick E., Laird N., Petersen L.A., et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997, 277:307-311.
25. Pugh M.J., Van Cott A.C., Cramer J.A., Knoefel J.E., Amuan M.E., Tabares J., et al. Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000-2004. Neurology 2008, 70:2171-2178.
26. Rytter E., Landmark C.J., Johannessen S.I. Antiepileptic drug treatment of children at a referral centre for epilepsy-does admission make a difference?. Seizure 2009, 18:573-579.
27. Johannessen Landmark C., Patsalos P.N. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010, 10:119-140.
28. Ucar M., Neuvonen M., Luurila H., Dahlqvist R., Neuvonen P.J., Mjörndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 2004, 59:879-882.
29. Murphy M.J., Dominiczak M.H. Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J 1999, 75:359-360.
30. Brämswig S., Kerksiek A., Sudhop T., Luers C., Von Bergmann K., Berthold H.K. Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. Am J Physiol Heart Circ Physiol 2002, 282:H704-H716.
31. James G.K., Jones M.W., Pudek M.R. Homocyst(e)ine levels in patients on phenytoin therapy. Clin Biochem 1997, 30:647-649.
32. Martí-Fàbregas J., Gomis M., Arboix A., Aleu A., Pagonabarraga J., Belvís R., et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004, 35:1117-1121.
33. Leker R.R., Khoury S.T., Rafaeli G., Shwartz R., Eichel R., Tanne D., et al. Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS). Stroke 2009, 40:2581-2584.
34. Hsieh C.Y., Lai E.C., Yang Y.H., Lin S.J. Comparative stroke risk of antiepileptic drugs in patients with epilepsy. Epilepsia 2013, 54:172-180.
35. Gaitatzis A., Trimble M.R., Sander J.W. The psychiatric comorbidity of epilepsy. Acta Neurol Scand 2004, 110:207-220.
36. Hoppe C., Elger C.E. Depression in epilepsy: a critical review from a clinical perspective. Nat Rev Neurol 2011, 7:462-472.
37. Kerr M.P., Mensah S., Besag F., de Toffol B., Ettinger A., Kanemoto K., et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011, 52:2133-2138.
38. Thummel K.E., Shen D.D., Isoherranen N., Smith H.E. Design and optimization of dosage regimens: pharmacokinetic data. Goodman & Gilman's the pharmacological basis of therapeutics 2006, 1787-1888. McGraw-Hill, New York. 11 ed. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
39. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors?. Seizure 2008, 17:181-186.
40. Kane G.C., Lipsky J.J. Drug-grapefruit juice interactions. Mayo Clin Proc 2000, 75:933-942.
41. Garg S.K., Kumar N., Bhargava V.K., Prabhakar S.K. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther 1998, 64:286-288.
42. Product information: Tegretol, Tegretol XR 2011, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
43. Huying F., Klimpe S., Werhahn K.J. Antiepileptic drug use in nursing home residents: a cross-sectional, regional study. Seizure 2006, 15:194-197.
44. Tomson T., Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol 2012, 11:803-813.
45. Soldin O.P., Mattison D.R. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009, 48:143-157.
46. Barcellona D., Contu P., Marongiu F. Patient education and oral anticoagulant therapy. Haematologica 2002, 87:1081-1086.
47. Tang E.O., Lai C.S., Lee K.K., Wong R.S., Cheng G., Chan T.Y. Relationship between patients' warfarin knowledge and anticoagulation control. Ann Pharmacother 2003, 37:34-39.
48. Verhovsek M., Motlagh B., Crowther M.A., Kennedy C., Dolovich L., Campbell G., et al. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. BMC Geriatr 2008, 8:13.